BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10608394)

  • 1. MultiHance in the assessment of intracranial tumors: results of phase II clinical studies.
    Ruscalleda J; Kirchin MA; La Noce A; Pirovano G; Spinazzi A
    J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S19-27. PubMed ID: 10608394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical late phase II trials of MultiHance (Gd-BOPTA) for the magnetic resonance imaging of liver tumors in Japan.
    Kuwatsuru R; Kadoya M; Ohtomo K; Tanimoto A; Hirohashi S; Murakami T; Tanaka Y; Yoshikawa K; Katayama H
    J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S65-74. PubMed ID: 10608400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-field, high-resolution, susceptibility-weighted magnetic resonance imaging: improved image quality by addition of contrast agent and higher field strength in patients with brain tumors.
    Pinker K; Noebauer-Huhmann IM; Stavrou I; Hoeftberger R; Szomolanyi P; Weber M; Stadlbauer A; Grabner G; Knosp E; Trattnig S
    Neuroradiology; 2008 Jan; 50(1):9-16. PubMed ID: 17876570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Off-site evaluation of liver lesion detection by Gd-BOPTA-enhanced MR imaging.
    Gehl HB; Bourne M; Grazioli L; Möller A; Lodemann KP
    Eur Radiol; 2001; 11(2):187-92. PubMed ID: 11218012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of a high relaxivity contrast agent administered at half dose in dynamic susceptibility contrast MRI of brain gliomas.
    Crisi G; Filice S; Erb G; Bozzetti F
    J Magn Reson Imaging; 2017 Feb; 45(2):500-506. PubMed ID: 27373976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases.
    Yuh WT; Fisher DJ; Runge VM; Atlas SW; Harms SE; Maravilla KR; Mayr NA; Mollman JE; Price AC
    AJNR Am J Neuroradiol; 1994 Jun; 15(6):1037-51. PubMed ID: 8073972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.
    Knopp MV; Runge VM; Essig M; Hartman M; Jansen O; Kirchin MA; Moeller A; Seeberg AH; Lodemann KP
    Radiology; 2004 Jan; 230(1):55-64. PubMed ID: 14695387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The advantage of high relaxivity contrast agents in brain perfusion.
    Cotton F; Hermier M
    Eur Radiol; 2006 Nov; 16 Suppl 7():M16-26. PubMed ID: 18655263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance imaging of metastatic disease to the brain with gadobenate dimeglumine.
    Balériaux D; Colosimo C; Ruscalleda J; Korves M; Schneider G; Bohndorf K; Bongartz G; van Buchem MA; Reiser M; Sartor K; Bourne MW; Parizel PM; Cherryman GR; Salerio I; La Noce A; Pirovano G; Kirchin MA; Spinazzi A
    Neuroradiology; 2002 Mar; 44(3):191-203. PubMed ID: 11942372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine.
    Knopp MV; Bourne MW; Sardanelli F; Wasser MN; Bonomo L; Boetes C; Müller-Schimpfle M; Hall-Craggs MA; Hamm B; Orlacchio A; Bartolozzi C; Kessler M; Fischer U; Schneider G; Oudkerk M; Teh WL; Gehl HB; Salerio I; Pirovano G; La Noce A; Kirchin MA; Spinazzi A
    AJR Am J Roentgenol; 2003 Sep; 181(3):663-76. PubMed ID: 12933457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.
    Katakami N; Inaba Y; Sugata S; Tsurusaki M; Itoh T; Machida T; Tanaka H; Nakayama T; Morikawa T; Breuer J; Aitoku Y
    Invest Radiol; 2011 Jul; 46(7):411-8. PubMed ID: 21467949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MultiHance in the dynamic phase of contrast enhancement: a pictorial assessment.
    Grazioli L; Kirchin M; Pirovano G; Spinazzi A
    J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S61-4. PubMed ID: 10608399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MultiHance in brain perfusion.
    Essig M
    Eur Radiol; 2004 Jun; 14 Suppl 7():O10-5; discussion O20-1. PubMed ID: 15503371
    [No Abstract]   [Full Text] [Related]  

  • 14. Diffusion-perfusion in intra-axial brain tumors with high relaxivity contrast agents.
    Cotton F
    Neuroradiology; 2006 Apr; 48 Suppl 1():34-40. PubMed ID: 16699850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of the efficacy of gadobutrol and multihance in contrast-enhanced MRI for diagnosis of brain metastasis in lung cancer].
    Li ZL; Chen X; Xia CC; Sun JY; Li CX; Tang HH; Song B
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Jul; 43(4):601-4. PubMed ID: 22997905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inter- and intra-individual comparative study of two gadolinium-based agents: A pilot study.
    Shin KS; AlObaidy M; Ramalho M; Jeon YH; Burke LM; Altun E; Stallings CG; Semelka RC
    Abdom Imaging; 2015 Apr; 40(4):865-74. PubMed ID: 25223524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gadobenate dimeglumine-enhanced magnetic resonance imaging of intracranial metastases: effect of dose on lesion detection and delineation.
    Schneider G; Kirchin MA; Pirovano G; Colosimo C; Ruscalleda J; Korves M; Salerio I; La Noce A; Spinazzi A
    J Magn Reson Imaging; 2001 Nov; 14(5):525-39. PubMed ID: 11747004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain metastases--comparison of gadodiamide injection-enhanced MR imaging at standard and high dose, contrast-enhanced CT and non-contrast-enhanced MR imaging.
    Akeson P; Larsson EM; Kristoffersen DT; Jonsson E; Holtås S
    Acta Radiol; 1995 May; 36(3):300-6. PubMed ID: 7742127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MR imaging of the gastrointestinal tract with i.v., gadolinium and diluted barium oral contrast media compared with unenhanced MR imaging and CT.
    Low RN; Francis IR
    AJR Am J Roentgenol; 1997 Oct; 169(4):1051-9. PubMed ID: 9308464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of myocardial response in CMR perfusion imaging using Gd-BOPTA (Multihance).
    Gebker R; Paetsch I; Neuss M; Schnackenburg B; Bornstedt A; Jahnke C; Gomaa O; Fleck E; Nagel E
    J Cardiovasc Magn Reson; 2005; 7(3):565-72. PubMed ID: 15959969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.